Business Wire

FL-AMGTA

17.11.2020 14:01:06 CET | Business Wire | Press release

Share
AMGTA Publishes First Research Paper on Sustainability in Additive Manufacturing

The Additive Manufacturer Green Trade Association (AMGTA), a global trade group created to foster and promote the environmental benefits of additive manufacturing (AM), announced today the publication of its first commissioned university research project, a literature-based systematic review of the environmental benefits of metal AM. The paper, titled, “State of Knowledge on the Environmental Impacts of Metal Additive Manufacturing” was written by Dr. Jeremy Faludi from Delft University of Technology and Corrie Van Sice from Dartmouth College.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005440/en/

Key takeaways from the report include that, while “AM generally has much higher carbon footprints per kg of material processed than CM [conventional manufacturing] when considering the direct manufacturing process itself”, but “impacts depend greatly on part geometry—a solid cube will be much lower impact to produce by machining, while a hollow shell or lattice can be lower impact to produce by AM.” The report further recognizes the need for additional life cycle assessment (LCA) studies to quantify environmental impacts: “More LCA studies are necessary to definitively compare metal AM to CM; especially direct comparisons of AM to machining, and especially for technologies such as binder jetting and DED. These LCAs should ideally also include more of the product life cycle.”

“We were pleased to work with Dr. Faludi and Ms. Van Sice on this study,” said Sherry Handel, the Executive Director of the AMGTA. “No one should expect metal AM to be a more sustainable way to manufacture basic metal parts given the focused energy inherent in laser melting, but AM should present a more sustainable course for manufacturing finished precision components.” Ms. Handel continued, “These findings validate the AMGTA’s plans to provide the industry with rigorous, independent, and ongoing research. The AMGTA will continue to commission studies and publish research findings in an effort to update the industry and other key stakeholders on what our eco-footprint is now and what we will need to focus on in the future to be more sustainable.”

About the Researchers

Jeremy Faludi, Ph.D., a leading sustainable engineering researcher, was selected by the AMGTA to oversee this project. Dr. Faludi is assistant professor of design engineering at Delft University of Technology, where he specializes in sustainable design methods and green 3D printing, and adjunct faculty of engineering at the Thayer School of Engineering at Dartmouth College. Dr. Faludi earned a Ph.D. in Mechanical Engineering at University of California Berkeley, a Master of Engineering in Product Design at Stanford University, and a B.A. in Physics from Reed College.

Corrie Van Sice was a senior research engineer at the Faludi Lab at the Thayer School of Engineering, Dartmouth College. Ms. Van Sice managed the Green 3D Printing Lab and assessed AM techniques to define best practices for sustainability in the industry. Before joining the Faludi Lab, she was the lead Materials and Processes R&D Engineer at MakerBot Industries in Brooklyn, NY where she developed and scaled print material manufacturing. Ms. Van Sice earned a Master of Professional Studies from the Interactive Telecommunications Program at New York University in 2011.

About AMGTA

The AMGTA was launched in November 2019 to promote the environmental benefits of additive manufacturing (AM) over traditional methods of manufacturing. The AMGTA is a non-commercial, unaffiliated organization open to any additive manufacturer or industry stakeholder that meets certain criteria relating to sustainability of production or process.

Founding Members of the AMGTA include Sintavia, LLC , a leading additive manufacturer focused on the aerospace, defense, and space industry; Taiyo Nippon Sanso Corporation (one of the operating companies under Nippon Sanso Holdings Corporation), a supplier of stable industrial gases to a wide variety of global industries; and QC Laboratories, Inc. , an industrial and commercial non-destructive testing laboratory focused on AM components.

Participating Members of the AMGTA include AMEXCI AB , Danish AM Hub , EOS , GE Additive , Materialise , National Manufacturing Institute Scotland , Siemens Digital Industries Software , SLM Solutions Inc. , and Stryker .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye